全文获取类型
收费全文 | 29307篇 |
免费 | 2174篇 |
国内免费 | 1113篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 793篇 |
妇产科学 | 166篇 |
基础医学 | 3468篇 |
口腔科学 | 264篇 |
临床医学 | 2836篇 |
内科学 | 6011篇 |
皮肤病学 | 193篇 |
神经病学 | 1848篇 |
特种医学 | 514篇 |
外国民族医学 | 6篇 |
外科学 | 2104篇 |
综合类 | 4775篇 |
现状与发展 | 4篇 |
预防医学 | 1385篇 |
眼科学 | 97篇 |
药学 | 5638篇 |
4篇 | |
中国医学 | 1563篇 |
肿瘤学 | 874篇 |
出版年
2024年 | 85篇 |
2023年 | 407篇 |
2022年 | 847篇 |
2021年 | 1051篇 |
2020年 | 847篇 |
2019年 | 863篇 |
2018年 | 767篇 |
2017年 | 875篇 |
2016年 | 907篇 |
2015年 | 1012篇 |
2014年 | 1664篇 |
2013年 | 2080篇 |
2012年 | 1629篇 |
2011年 | 1849篇 |
2010年 | 1486篇 |
2009年 | 1367篇 |
2008年 | 1305篇 |
2007年 | 1350篇 |
2006年 | 1285篇 |
2005年 | 1163篇 |
2004年 | 976篇 |
2003年 | 923篇 |
2002年 | 729篇 |
2001年 | 685篇 |
2000年 | 628篇 |
1999年 | 522篇 |
1998年 | 473篇 |
1997年 | 484篇 |
1996年 | 437篇 |
1995年 | 395篇 |
1994年 | 397篇 |
1993年 | 367篇 |
1992年 | 313篇 |
1991年 | 272篇 |
1990年 | 280篇 |
1989年 | 256篇 |
1988年 | 222篇 |
1987年 | 196篇 |
1986年 | 169篇 |
1985年 | 186篇 |
1984年 | 145篇 |
1983年 | 136篇 |
1982年 | 122篇 |
1981年 | 109篇 |
1980年 | 100篇 |
1979年 | 79篇 |
1978年 | 48篇 |
1977年 | 28篇 |
1976年 | 18篇 |
1974年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
I.J. Clifton A.M. Morton N.S. Ambrose D.G. Peckham S.P. Conway 《Journal of cystic fibrosis》2004,3(4):273-275
We report a case of a patient with CF who had a long history of recurrent distal intestinal obstruction syndrome. She had been treated with conventional treatment including gastrografin, n-acetyl cysteine, Klean prep and Picolax. She underwent a modified antegrade continence enema procedure. She currently irrigates her conduit every 2-3 days. She has had no further symptoms of distal intestinal obstruction syndrome. 相似文献
62.
Jonas Bergstrm Mahmood Ahmed Jian Li Tashfeen Ahmad Andris Kreicbergs Mariana Spetea 《Journal of orthopaedic research》2006,24(6):1193-1199
Using immunohistochemical and biochemical techniques, the occurrence of endogenous opioid peptides and their receptors in normal rat bone and joint tissues was investigated. Opioid receptors were detected, quantified, and characterized in homogenates from capsule/synovium and periosteum using radioligand binding assays. Receptor binding of the nonselective opioid [3H]naloxone to tissue homogenates was stereospecific and saturable, showing similar characteristics to that of brain tissue, although with lower binding capacities. By immunohistochemistry, the neuronal occurrence of four different enkephalins was demonstrated in synovium, bone marrow, periosteum, and juxta-articular bone, whereas no neuronal dynorphin immunoreactivity was detected. Double-staining studies disclosed that enkephalins coexisted with substance P in primary afferent fibers. The applied techniques can be used to assess changes in the distribution of endogenous opioids and their receptors in joint tissues in conditions associated with pain and inflammation. The endogenous opioid system now demonstrated might be targeted and exploited therapeutically to obtain peripheral control of symptoms in joint disorders. 相似文献
63.
Ken Yamaguchi Katsumi Aoyagi Ken-ichi Urakami Toyoharu Fukutani Noboru Maki Shigehiro Yamamoto Kotomi Otsubo Yoshio Miyake Tetsuro Kodama 《Cancer science》1995,86(7):698-705
Our previous study demonstrated that pro-gastrin-releasing peptide(31–98), or ProGRP, is a specific tumor marker in patients with small cell lung carcinoma (SCLC). Using a newly developed, highly sensitive enzyme-linked immunosorbent assay (ELISA) for ProGRP, we analyzed 1,446 samples including those obtained from 478 lung cancer patients to evaluate the clinical usefulness of this ELISA. Several properties indicated that ProGRP is a useful tumor marker for SCLC. First, ProGRP was specifically elevated in SCLC patients. In non-SCLC patients and patients with non-tumorous lung diseases, its serum level was very rarely elevated. Secondly, ProGRP was a reliable marker, in terms of the marked elevation of serum ProGRP levels in SCLC patients. Thirdly, serum ProGRP levels were elevated in SCLC patients even at a relatively early stage of this disease. Fourthly, changes in the serum ProGRP level showed an excellent correlation with the therapeutic responses in SCLC patients. Neuron-specific enolase (NSE) is accepted as a tumor marker of SCLC patients. With the aim of comparing ProGRP and NSE as tumor markers for SCLC patients, we measured serum NSE levels in all samples collected in the present study. We found that ProGRP was superior to NSE in terms of sensitivity, specificity and reliability. Therefore, we consider that ProGRP can play a major role as a clinical tumor marker for SCLC patients. 相似文献
64.
大肠癌旁粘膜细胞的PCNA和AgNORs表达观察 总被引:2,自引:0,他引:2
用增殖细胞核抗原(PCNA)和核仁组成区嗜银蛋白(AgNORs)对35例大肠癌旁粘膜进行细胞增殖表达与观察。结果表明:癌旁粘膜的PCNA标记指数增多,标记增强,排列紊乱。AgNORs在癌旁粘膜中,颗粒增多、增大,形态多样,0 ̄1cm和2 ̄3cm组的标记指数与4 ̄5cm组的标记指数相比较,有显著或非常显著差异(P〈0.05或P〈0.01)。在DukeA、B期中,细胞标记指数增高增强,与癌的发生和患者 相似文献
65.
SEVERO SALVADORI REMO GUERRINI PIERO ANDREA BOREA ROBERTO TOMATIS 《Chemical biology & drug design》1992,40(5):437-444
The synthesis of pseudotetrapeptides H-Tyr-D-Ala-Phe-NH-(CH2)2-NH2 (1a), H-Tyr-D-Ala-Phe-ψ(CH2-NH)-Gly-NH2 (2a), H-Tyr-D-Ala-ψ(CH2-NH)-Phe-Gly-NH2 (3a), and H-Tyr-ψ(CH2-NH)-D-Ala-Phe-Gly-NH2 (4a), representing the N-terminal tetrapeptide sequence of dermorphin, in which amide bonds are replaced by CH2-NH bond, is described. N-acetyl-Tyr and desamino-Tyr pseudopeptide analogs (1-4b), (1-3c) are also described. The analogs were assayed in binding studies based on displacement of μ and δ-receptor selective radiolabels from rat brain membrane and in a bioassay using guinea pig ileum (GPI). Pseudopeptides in which the C-terminal (1a) or D-Ala-Phe (3a) amide bond are substituted, exhibit higher μ-affinities and μ-receptor selectivity than the corresponding Phe-Gly or Tyr-D-Ala analogs (2a, 4a). Acetyl-and desamino-Tyr pseudopeptide analogs (1-4b) and (1-3c) did not exhibit μ and δ-opioid receptor affinity at nM concentration. The relevance of the single peptide replacement and of its association to acetylation or amino group elimination of Tyr, is discussed on the basis of a receptor model for μ and δ opioids. 相似文献
66.
The effects of quercetin have been investigated on the gastrointestinal propulsion of charcoal meal in mice. Quercetin reduced the rate of intestinal transit and this effect was potentiated by verapamil. 相似文献
67.
The effects of treatment with a bombesin receptor antagonist [D-Tpi6, Leu13 psi (CH2NH) Leu14]BN(6-14)(RC-3095) and the combination of an agonist of luteinizing hormone-releasing hormone [D-Trp6]-LH-RH and somatostatin analog D-Phe-Cys-Tyr-D-Trp-Lys-Val- Cys-Trp-NH2 (RC-160) were studied in nude mice bearing xenografts of the hormone-dependent human prostate tumor PC-82. During the 5 weeks of treatment, tumor growth was decreased in all treated groups compared with controls. Bombesin antagonist RC-3095 and the combination of [D-Trp6]-LH-RH and RC-160 caused a greater inhibition of tumor growth than [D-Trp6]-LH-RH or RC-160 alone as based on measurement of tumor volume and percentage change in tumor volume. The largest decrease in tumor weight was also seen in the groups treated with the bombesin antagonist and with the combination of RC-160 and [D-Trp6]-LH-RH. Serum prostatic-specific antigen levels were greatly decreased, and insulin-like growth factor I (IGF-I) as well as growth hormone levels were reduced in all treated groups. Specific binding sites for [D-Trp6]-LH-RH, epidermal growth factor (EGF), IGF-I, and somatostatin (SS-14) were found in the tumor membranes. Receptors for EGF were significantly down-regulated by treatment with the bombesin antagonist or RC-160. Combination of LH-RH agonists with somatostatin analog RC-160 might be considered for improvement of hormonal therapy for prostate cancer. The finding that bombesin antagonist RC-3095 inhibits the growth of PC-82 prostate cancer suggests the merit of further studies to evaluate the possible usefulness of antagonists of bombesin in the management of prostatic carcinoma. 相似文献
68.
69.
Joen-Rong sheu Chao-Hsin Lin Jih-Luan chung Che-Ming Teng Tur-Fu Huang 《Thrombosis research》1992,66(6):679-691
Triflavin, an Arg-Gly-Asp (RGD)-containing peptide, purified from snake venom of Trimeresurus flavoviridis, inhibits human platelet aggregation through the blockade of fibrinogen binding to fibrinogen receptors associated with glycoprotein IIb/IIIa complex. In this report, we examined the effect of triflavin on tumor cells (human hepatoma J-5)-induced platelet aggregation (TCIPA) of heparinized platelet-rich plasma (PRP). ADP-scavenger agents, apyrase (10 U/ml) and creatine phosphate (5 mM)/creatine phosphokinase (5 U/ml) did not inhibit TCIPA while hirudin (5u/ml) completely inhibited it. J-5 cells initially induced platelet aggregation, then blood coagulation occurred. J-5 cells concentration-dependently shortened the recalcification time of normal as well as Factor VIII, IX-deficient human plasmas, while it was inactive at shortening the recalcification time of Factor VII-deficient plasma, suggesting J-5 cells induced platelet aggregation through activation of extrinsic pathway, leading to thrombin formation as evidenced by the amidolytic activity on S-2238 by expressing tissue factor-like activity. Triflavin inhibited TCIPA in a dose-dependent manner (IC50, 0.02 μM). When compared on molar ratio, triflavin was approximately 30,000 times more potent than GRGDS (IC50,0.58 mM). On the other hand, GRGES showed no significant effect on TCIPA, even its concentration was raised to 4 mM. Additionally, the monoclonal antibodies, raised against glycoprotein IIb/IIIa complex (i.e., 7E3 and 10 E5) inhibited J-5 TCIPA. In conclusion, we suggest the inhibitory effect of triflavin on J-5 TCIPA may be chiefly mediated by the binding of triflavin to the fibrinogen receptor associated with glycoprotein IIb/IIIa complex on platelet surface membrane. 相似文献
70.
Vasoactive intestinal peptide (VIP), the structurally homologous pituitary adenylate cyclase-activating peptide (PACAP) and the pituitary hormone, prolactin (PRL) enhance rapid eye movement sleep (REMS). VIP and PACAP are both inducers of PRL gene expression and release in the pituitary gland. Little is known about PRL regulation in the brain although it is hypothesized that the REMS-promoting activity of i.c.v. administered VIP may be mediated via the activation of cerebral PRL. To test whether VIP or PACAP in fact increase intracerebral mRNA, the peptides (VIP: 30 or 300 pmol; PACAP: 220 pmol) were injected i.c.v. into rats at dark onset. 1 h later, cDNA was synthesized from purified hypothalamic mRNA. Standardized amounts were analysed for PRL using the polymerase chain reaction followed by Southern blotting and hybridization. Compared with β-actin mRNA levels, both VIP and PACAP increased PRL mRNA levels in a dose-dependent fashion though VIP was more effective on a molar basis. The previously reported alternatively spliced PRL mRNA (lacking exon 4) was not detected. The data support the hypothesis that the REMS-promoting activity of central VIP and PACAP might be mediated by cerebral PRL. 相似文献